The Odisha market grew the highest followed by Mumbai City Market and Karnataka
The Indian Pharmaceutical Market clocked Rs 8449 crores in May 2016 and has witnessed a growth of 7.7 per cent for the month of May 2016. Amongst the top 10, Mankind grew at 18.7 per cent, Abbott at 11.4 per cent followed by Alkem at 10.6 per cent. 18 corporates have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporate, Bharat Serum registered the highest growth of 42.8 per cent followed by Wallace at 29.5 per cent and Eris at 24.4 per cent. 18 corporates have shown growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Intas had the highest growth of 15.2 per cent followed by Micro at 14.2 per cent and Alembic at 11.3 per cent. Amongst the 21-30 ranked corporates, Eris had the highest growth at 24.4 per cent followed by Novartis at 9.5 per cent and Wockhardt at 9.4 per cent. Amongst the 31-40 ranked corporate, Bharat Serums grew at 42.8 per cent followed by Wallace at 29.5 per cent and Akumentis at 19.5 per cent. Amongst the 41-50 ranked corporates, Systopic grew at 20.5 per cent followed by Janssen at 18 per cent and Win-Medicare at 17.3 per cent. Amongst the 51-60 ranked corporates, Boehringer grew at 52.5 per cent followed by Fresenius Kabi at 48.1 per cent and Corona at 28 per cent. Amongst the 61-70 ranked corporates, Shreya grew at 21.6 per cent followed by RPG grew at 11.8 per cent and Tablets India at 9.3 per cent. Amongst the 71-80 ranked corporates, Dabur grew at 60.8 per cent followed by Samarth, which grew at 32.4 per cent and Danone at 17.7 per cent. Amongst the 81 -90 ranked corporates, Paras grew at 44.2 per cent followed by Veritaz, which grew at 38.5 per cent followed by Galderma at 30.2 per cent. Amongst the 91- 100 ranked corporates, Ind-Swift grew at 63.1 per cent followed by Ordain at 32.4 per cent and Curatio at 31.8 per cent.
Mercury entered the Rs 50-crore club on MAT Basis. The 100th biggest corporate is Ordain and 150th biggest corporate is UTH in the IPM.
Abbott HC grew at 12.5 per cent whereas Abbott India grew at 13.1 per cent for the month of May 2016. Zuventus grew at 13.6 per cent. Indian companies have grown at 7.9 per cent versus 7 per cent for MNCs in May 2016. Amongst the top 50 in MNCs, Janssen grew at 18 per cent followed by Abbott at 11.4 per cent and Novartis at 9.5 per cent.
Under the Non-NLEM category, Indian companies grew at nine per cent whereas MNCs grew at 7.1 per cent.
The NLEM 2013 containing molecules market grew at 2.6 per cent whereas the non DPCO market grew by 8.6 per cent resulting in an overall growth of 7.7per cent for May 2016. NLEM & Non – NLEM category showed unit growth of 0.8 per cent and -3.1 per cent respectively. From therapy perspective, 14 therapies have outgrown the IPM growth. The respiratory market grew at 0.6 per cent, gastrointestinal market grew at 5.9 per cent, pain and analgesics market grew at 5.1 per cent whereas anti-infectives grew at 2.7 per cent. The anti-diabetic market grew at 14.9 per cent and cardiac at 10.2 per cent, Neuro/ CNS at 10.3 per cent in chronic business. The anti-malarials grew at -13.2 per cent, VMS market at 9.8 per cent. The derma market grew by 8.6 per cent and urology market at 11.3 per cent.
From regional perspective, 15 regions have outgrown the IPM growth. The Odisha market grew the highest at 14.2 per cent followed by Mumbai City Market at 13.8 per cent and Karnataka market at 13.5 per cent. One region had negative growth in May 2016.
In molecules segment, Amoxycillin + Clavulanic Acid market grew at 2.8 per cent and Glimepiride + Metformin market grew at 20.2 per cent. The markets of paracetamol grew at 14 per cent, Atorvastatin -1.0 per cent, probiotic microbes at 17.1 per cent, Bacillus Clausii market at 27.2 per cent, Cefixime at 5.7 per cent, pantoprazole at 10.7 per cent, Montelukast + Levocetrizine at 0.3 per cent, Glimepiride + Metformin + Pioglitazone at -10.4 per cent, Vitamin-D at 18.9 per cent, Hydroquinone + Mometasone + Tretinoin at 7.8 per cent, Voglibose + Metformin + Glimepiride at 43.9 per cent, Rosuvastatin at 17.2 per cent, Protein Supplements at 13.5 per cent, Azithromycin at -9.1 per cent, Calcium Carbonate + Vit D3 market at 2.7 per cent, Paracetamol + Phenylephrine + Chlorpheniramine at -2.8 per cent, Meropenem at 34.1per cent, Montelukast + Fexofenadine at 8.1 per cent Diclofenac at 16.6 per cent, Telmisartan at 0.8 per cent, Levetiracetam at 19.6 per cent.
The 50th biggest market was Sildenafil and 100th biggest market is Paracetamol + Tramadol for May 16.
Mixtard led the pack with Rs 37 crores followed by Glycomet GP at Rs 31 crores, Lantus at Rs 27 crores and Galvus Met at Rs 25 crores for May 2016.
Few brands who have gained ranks includeRotarix (+366), Meronem (+70), Revital H (+67), Clexane (+39), Unwanted Kit (+39), Trajenta (+31), Mucaine (+28), Udiliv (+25), Rosuvas (+22), Minipress XL, Levera (+19), Synflorix, Budecort (+17), Duphaston (+16), Januvia, Ultracet, Novomix (+15), Volini, Istamet, Rantac (+13), Taxim O, Telma H, Eltroxin (+12),Galvus Met, Zifi, Levipil, Gluconorm G (+10), Pan D, Atorva (+9), Calpol (+8), Pantop (+7), Lantus, Voveran, Skinlite (+6), Cores, Phensedyl, Thyronorm, Gemer, Jalra M, Sinarest, Dolonex (+5), Betadine, Duolin (+4), Janumet, Clavam (+3), Pan (+1) amongst top 100 Brands over May 2015.
Razo D, Glimestar M, Lonopin, Acitrom, Kenacort, Cilacar, Practin, Phexin, Wysolone are few brands gained ranks in 101-200 ranked brands.
Few brands that have moved up ranks fastest into Top 300 Brands for the month of May – 16 are Mifty, Hucog HP, Imicrit, Plavix, Trajenta Duo, Rotarix, Razo D. The 300th biggest brand is Ferium XT from Emcure.
The total 360 brands and 608 SKUs were launched in May 2016. The Top 3 new brands for May 2016 were Sofocure, Panderm NM and Cabtana. Sanofi launched Lixisenatide – Lyxumia and Novartis launched Ruxolitinib – Jakavi. The three brands launched each in Teneligliptin Combination with Metformin – Tenepride M, Afoglip M, Ten M & 1 in Teneligliptin – Megagliptin. Within the VMS category, Able TO (MMC), Folactib-D (Vidakem), Bonmax CCM (Zydus) were launched followed by Lyxumia (Sanofi), Tenepride M (Micro) & Megagliptin (Aristo) within anti-diabetic, Panderm NM (Macleods), Lipbless (Zydus) & Zocon KZ (FDC) within derma, Ferisome (Micro), Femozer Plus & Femozer (Leeford) within gynaec, XT Para Life (Unichem), Zeldinac (Leeford), Panzox ( Micro) in pain and analgesics category, Sinarest New (Centaur), Cuflit (Leeford), Lukostas HD (Intas) in respiratory, Exenta T, Exenta (Alembic), Telmeron AM (Saffron) in cardiac and Office OZ (Hetero), Unipan (Kontest), Rabiwok D (Wockhardt) in gastro intestinal. The biggest new launch by a MNC was Mydacla from Mylan in May 2016.
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocdawacs.com